2seventy bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSVT research report →
Companywww.2seventybio.com
2seventy bio, Inc. , a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.
- CEO
- William D. Baird III,
- IPO
- 2021
- Employees
- 65
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $266.14M
- P/E
- -13.93
- P/S
- 10.29
- P/B
- 1.24
- EV/EBITDA
- -18.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 45.89%
- Op Margin
- -99.70%
- Net Margin
- -73.61%
- ROE
- -8.96%
- ROIC
- -5.46%
Growth & Income
- Revenue
- $37.86M · -62.28%
- Net Income
- $-57,247,000 · 73.69%
- EPS
- $-1.10 · 75.11%
- Op Income
- $-115,430,000
- FCF YoY
- 52.58%
Performance & Tape
- 52W High
- $5.30
- 52W Low
- $2.29
- 50D MA
- $4.97
- 200D MA
- $4.05
- Beta
- 1.05
- Avg Volume
- 1.46M
Get TickerSpark's AI analysis on TSVT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 25 | Glickman Sarah JS | sell | 12,050 |
| May 13, 25 | Glickman Sarah JS | sell | 24,100 |
| May 13, 25 | Glickman Sarah JS | other | 15,602 |
| May 13, 25 | Casdin Capital, LLC | other | 2,000,000 |
| May 13, 25 | Casdin Capital, LLC | sell | 33,400 |
| May 13, 25 | Casdin Capital, LLC | sell | 12,050 |
| May 13, 25 | Leschly Nick | sell | 335,964 |
| May 13, 25 | Leschly Nick | sell | 469,000 |
| May 13, 25 | Leschly Nick | other | 41,000 |
| May 13, 25 | Eatwell Victoria | sell | 401,111 |
Our TSVT Coverage
We haven't published any research on TSVT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TSVT Report →